ReviewTrends in biotechnology2015
Synthetic biology in cell-based cancer immunotherapy.
Review in Trends in biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Induced Pluripotent Stem Cell-Derived NK Cells as an Off-the-Shelf Platform for Cancer Immunotherapy: Opportunities, Challenges, and Clinical Translation.Stem cell reviews and reports · 2026Review
- Engineering mammalian cells for detection and treatment of cardiac injury.Molecular systems biology · 2026Article
- Optimized pipeline and designer cells for synthetic-biology-based high-throughput screening of viral protease inhibitors.Cell reports methods · 2025Article
- Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Engineered Genetic Circuits Activated by Bezafibrate Improve ESC-Based TAA Cancer Vaccine Efficacy and PD-L1 Nanobody Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- PostFocus: automated selective post-acquisition high-throughput focus restoration using diffusion model for label-free time-lapse microscopy.Bioinformatics (Oxford, England) · 2024Article
- Engineering Versatile Nanomedicines for Ultrasonic Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Cellular and molecular imaging of CAR-T cell-based immunotherapy.Advanced drug delivery reviews · 2023Review
- Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development.Signal transduction and targeted therapy · 2023Review
- Safety risks and ethical governance of biomedical applications of synthetic biology.Frontiers in bioengineering and biotechnology · 2023Article
- Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Control of the activity of CAR-T cells within tumours via focused ultrasound.Nature biomedical engineering · 2021Article
- Pro- and anti-apoptotic fate decisions induced by di- and trimeric synthetic cytokine receptors.iScience · 2021Article
- Sentinel cells enable genetic detection of SARS-CoV-2 Spike protein.bioRxiv : the preprint server for biology · 2021Article
- Stability and Robustness of Unbalanced Genetic Toggle Switches in the Presence of Scarce Resources.Life (Basel, Switzerland) · 2021Article
- Engineering precision therapies: lessons and motivations from the clinic.Synthetic biology (Oxford, England) · 2021Review
- Synthetic biology in various cellular and molecular fields: applications, limitations, and perspective.Molecular biology reports · 2020Review
- Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Tuning the performance of CAR T cell immunotherapies.BMC biotechnology · 2019Review
- Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.ACS synthetic biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The adoptive transfer of genetically engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. This form of cellular immunotherapy presents a unique opportunity to incorporate advanced systems and synthetic biology approaches to create cancer therapeutics with novel functions. We first review the development of synthetic receptors, switches, and circuits to control the location, duration, and strength of T cell activity against tumors. In addition, we discuss the cellular engineering and genome editing of host cells (or the chassis) to improve the efficacy of cell-based cancer therapeutics, and to reduce the time and cost of manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.